相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial
Serena Tonstad et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
CB1 receptor antagonists: new discoveries leading to new perspectives
E. Kirilly et al.
Acta Physiologica (2011)
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
M. S. Kipnes et al.
DIABETES OBESITY & METABOLISM (2010)
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
L. J. Aronne et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
J. Proietto et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625
L. Zuurman et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Developing drug prototypes: pharmacology replaces safety and tolerability?
Adam F. Cohen
NATURE REVIEWS DRUG DISCOVERY (2010)
The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning?
F. J. Bermudez-Silva et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2010)
Randomized, controlled, double-blind trial of taranabant for smoking cessation
Mary F. Morrison et al.
PSYCHOPHARMACOLOGY (2010)
Biomarkers for the effects of cannabis and THC in healthy volunteers
Lineke Zuurman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Roger G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Guide to receptors and channels (GRAC), 3rd edition
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Effect of intrapulmonary tetrahydrocannabinol administration in humans
L. Zuurman et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids
A. Strougo et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
Marilyn A. Huestis et al.
PSYCHOPHARMACOLOGY (2007)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
C Cohen et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Diversity of mechanism-based pharmacodynamic models
DE Mager et al.
DRUG METABOLISM AND DISPOSITION (2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
CR Trillou et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2003)
SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
C Cohen et al.
BEHAVIOURAL PHARMACOLOGY (2002)
Blockade of effects of smoked marijuana by the CBl-selective cannabinoid receptor antagonist SR141716
MA Huestis et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
分享论文
